Celyad Priced, Nasdaq: CYAD

Belgian biotech developing gene therapies for cardiovascular diseases and cancer.

Industry: Health Care

Latest Trade: $42.50 -1.87 (-4.2%)

First Day Return: -20.4%

Return from IPO: -35.3%

Industry: Health Care

We are a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Our lead drug product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. We completed enrollment in our first Phase 3 clinical trial of C-Cure in Europe and Israel, or CHART-1, in March 2015. On March 30, 2015, we announced that the Data Safety Monitoring Board, or DSMB, reviewed unblinded safety and efficacy data from CHART-1 and determined that such unblinded safety and efficacy data did not support the discontinuation of the trial on the basis of safety or futility. These observations suggested that the trial should be continued in its current form. The full data readout from this trial is expected in the middle of 2016. We anticipate initiating our second Phase 3 clinical trial of C-Cure in the United States and Europe, or CHART-2, pending FDA lifting of the existing clinical hold, which we expect in the second half of 2015. Our lead drug product candidate in oncology is CAR-NKG2D, an autologous chimeric antigen receptor, an artificial, lab engineered receptor, which is used to graft a given protein onto an immune cell, T lymphocyte, or CAR T-cell, therapy. We are currently enrolling patients with refractory or relapsed acute myeloid leukemia or multiple myeloma in a Phase 1 clinical trial of CAR-NKG2D in the United States. The first patient was treated in this trial in April 2015 and no treatment-related safety concerns were reported during the 30-day follow-up period. Interim data from this trial is expected to be reported at various times during the trial, with the full data readout expected in the middle of 2016.
more less
IPO News for Celyad
more
IPO Data
IPO File Date 05/18/2015
Offer Price $68.56
Price Range $68.56 - $68.56
Offer Shares (mm) 1.5
Deal Size ($mm) $100
IPO Data
IPO Date 06/18/2015
Offer Price $68.56
Price Range $68.56 - $68.56
Offer Shares (mm) 1.5
Deal Size ($mm) $100
Underwriters
more
Company Data
Headquarters Mont-Saint-Guibert, Belgium
Founded 2007
Employees 82
Website www.celyad.com